SC issues notices to Centre, others on Novartis petition
NAPHF | Quote | Chart | News | PowerRating -- The Supreme Court of India Friday issued notices to Indian government, pharma major Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on a pettion filed by Swiss firm Novartis AG challenging the denial of patent for its blood cancer drug Glivec in beta crystal form.
A Bench headed by Justice Dalveer Bhandari sought replies from the Ministry of Industry and Commerce, the Comptroller General of Patent and Design, the Cancer Patient Aid Association and the four pharma companies.
The Intellectual Property Appellate Board (IPAB) in July rejected Novartis' appeal against a Chennai patent office's decision to deny patent.
The patent was denied based on several grounds, including Sections 3(d) and 3(b) of the Indian Patent Law.
Section 3(d) of the Patent Law restricts patents for already known drugs unless the new claims are superior in terms of efficacy. Section 3(b) restricts patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products.
Novartis had obtained an exclusive marketing right (generic versions of Glivec were stopped from being made) in 2003 for the drug based on its patent application.
For full details on (NAPHF) NAPHF. (NAPHF) has Short Term PowerRatings at TradingMarkets. Details on (NAPHF) Short Term PowerRatings is available at This Link.
- Govt stays DCGI order against Natco Pharma; shares zoom 9 pc - 01/12/10
- INDIA'S NATCO PHARMA FLAYS TEVA FOR FILING CITIZEN PETITION - 11/27/09
- Indian pharma co criticises Israeli firm over citizen petition - 11/27/09
- Teva files lawsuit against Mylan and Natco Pharma for Copaxone - 10/19/09
- Local pharma firms get to retail generic flu drugs - 10/02/09
- More News >>


